Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Pharma
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
“What is clear is that we have found a better way to target HER2,” an ASCO-invited expert said, referring to Ziihera as better than Herceptin.
Angus Liu
Jan 6, 2026 3:25pm
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
FDA approves Regeneron's Libtayo for adjuvant use in CSCC
Oct 9, 2025 11:00am
Junshi, Coherus move Loqtorzi closer to another approval
Jun 12, 2024 11:45am
Summit and Akeso deliver Keytruda-topping results in NSCLC
May 31, 2024 11:00am
Merck's Keytruda misses the mark in endometrial cancer study
May 9, 2024 10:55am
